Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial

Cited by (1,098)

Items 201–300 of 1,098

1. Semaglutide 2.4 mg clinical outcomes in patients with obesity or overweight in a real‐world setting: A 6‐month retrospective study in the United States (SCOPE)
   Ruseva, Aleksandrina, Michalak, Wojciech, Zhao, Zhenxiang, Fabricatore, Anthony, Hartaigh, Bríain Ó., Umashanker, Devika · 2024 · Obesity Science & Practice
2. Review article: Pharmacologic management of obesity ‐ updates on approved medications, indications and risks
   Camille Lupianez‐Merly, Saam Dilmaghani, Kia Vosoughi, Michael Camilleri · 2024 · Alimentary Pharmacology & Therapeutics
3. Cardiovascular Benefits of GLP-1 Receptor Agonists in Patients Living with Obesity or Overweight: A Meta-analysis of Randomized Controlled Trials
   Gustavo de Oliveira Almeida, Thiago Faraco Nienkotter, Caroline Cristine Almeida Balieiro, Eric Pasqualotto, Júlia Braga Cintra, Henrique Champs Porfírio Carvalho, Ana Laura Soares Silva, Júlia Camargo Kabariti, Bárbara Silvestre Minucci, Edmundo Damiani Bertoli et al. · 2024 · American Journal of Cardiovascular Drugs
4. Semaglutide as a GLP-1 Agonist: A Breakthrough in Obesity Treatment
   Rui Salvador, Carla Maria Sanfins Guimarães Moutinho, Carla Sousa, Ana F. Vinha, Márcia C. Carvalho, Carla M. Matos · 2025 · Pharmaceuticals
5. Approved Anti-Obesity Medications in 2022 KSSO Guidelines and the Promise of Phase 3 Clinical Trials: Anti-Obesity Drugs in the Sky and on the Horizon
   Jeon, Eonju, Lee, Ki Young, Kim, Kyoung-Kon · 2023 · Journal of Obesity & Metabolic Syndrome
6. Effect of glucagon‐like peptide‐1 receptor agonists on cardiovascular events in overweight or obese adults without diabetes: A meta‐analysis of placebo‐controlled randomized trials
   Leite, Ana Rita, Angélico‐Gonçalves, António, Vasques‐Nóvoa, Francisco, Borges‐Canha, Marta, Leite‐Moreira, Adelino, Neves, João Sérgio, Ferreira, João Pedro · 2022 · Diabetes, Obesity and Metabolism
7. Major adverse cardiovascular events among patients with type-2 diabetes, a nationwide cohort study comparing primary metabolic and bariatric surgery to GLP-1 receptor agonist treatment
   Erik Stenberg, Erik B. Näslund · 2023 · International Journal of Obesity
8. Sex, race, and BMI in clinical trials of medications for obesity over the past three decades: a systematic review
   Moath S. Alsaqaaby, Sarah Cooney, Carel Wynand le Roux, Dimitri J. Pournaras · 2024 · The Lancet Diabetes & Endocrinology
9. A Comprehensive Review on Weight Gain following Discontinuation of Glucagon‐Like Peptide‐1 Receptor Agonists for Obesity
   Ibrahim Abdullah Bin Ahmed · 2024 · Journal of Obesity
10. Contemporary Classification of Glucagon-Like Peptide 1 Receptor Agonists (GLP1RAs)
    Sanjay Kalra, Saptarshi Bhattacharya, Nitin Kapoor · 2021 · Diabetes Therapy
11. What Is Best for Weight Loss? A Comparative Review of the Safety and Efficacy of Bariatric Surgery Versus Glucagon-Like Peptide-1 Analogue
    Nimra Klair, Utkarsh P. Patel, Ayushi Saxena, Dhara N. Patel, Ismat E Ayesha, Neetha R Monson, Shivana Ramphall · 2023 · Cureus
12. Advances in Anti-obesity Pharmacotherapy: Current Treatments, Emerging Therapies, and Challenges
    Skyler Brandfon, Adi Eylon, Deepesh Khanna, Mayur S. Parmar · 2023 · Cureus
13. AT-7687, a novel GIPR peptide antagonist, combined with a GLP-1 agonist, leads to enhanced weight loss and metabolic improvements in cynomolgus monkeys
    M. Jensen, Samra Joke Sanni, Ditte Riber, Jens Juul Holst, METTE MARIE ROSENKILDE, Alexander H. Sparre‐Ulrich · 2024 · Molecular Metabolism
14. Brown Adipose Tissue: A New Potential Target for Glucagon-like Peptide 1 Receptor Agonists in the Treatment of Obesity
    Hropot, Tim, Herman, Rok, Janez, Andrej, Lezaic, Luka, Jensterle, Mojca · 2023 · International Journal of Molecular Sciences
15. The past, present, and future of behavioral obesity treatment
    Chao, Ariana M., Moore, Molly, Wadden, Thomas A. · 2025 · International Journal of Obesity
16. Obesity as a risk factor for cardiac arrhythmias
    Kiran Haresh Kumar Patel, Rohin K. Reddy, Arunashis Sau, Pavidra Sivanandarajah, Maddalena Ardissino, Fu Siong Ng · 2022 · BMJ Medicine
17. Weight loss response to semaglutide in postmenopausal women with and without hormone therapy use
    Maria Daniela Hurtado, Elif Tama, Sima Fansa, Wissam Ghusn, Diego Añazco, Andres J Acosta, Stephanie S. Faubion, CHRISANDRA L. SHUFELT · 2024 · Menopause The Journal of The North American Menopause Society
18. Metabolic effects of very-low calorie diet, Semaglutide, or combination of the two, in individuals with type 2 diabetes mellitus
    Oluwaseun Anyiam, Bethan Eileen Phillips, Katie Quinn, Daniel James Wilkinson, Kenneth Smith, Philip James Atherton, ISKANDAR RAUF IDRIS · 2024 · Clinical Nutrition
19. Lifestyle interventions for cardiometabolic health
    Femke Rutters, Nicolette Roelina den Braver, Jeroen Lakerveld, Joreintje Dingena Mackenbach, Hidde P. van der Ploeg, Simon J. Griffin, Petra J. M. Elders, Joline W. J. Beulens · 2024 · Nature Medicine
20. Medical therapy to treat obesity and optimize fertility in women of reproductive age: a narrative review
    Janelle Duah, David B. Seifer · 2025 · Reproductive Biology and Endocrinology
21. Semaglutide in Obesity: Unmet Needs in Men
    Mojca Jensterle, Manfredi Rizzo, Andrej Janež · 2023 · Diabetes Therapy
22. GLP-1 receptor agonists, are we witnessing the emergence of a paradigm shift for neuro-cardio-metabolic disorders?
    Arredouani, Abdelilah · 2025 · Pharmacology & Therapeutics
23. Efficacy of Semaglutide in Treating Obesity: A Systematic Review of Randomized Controlled Trials (RCTs)
    Anam, Mahvish, Maharjan, Shrinkhala, Amjad, Zainab, Abaza, Abdelrahman, Vasavada, Advait M, Sadhu, Akhil, Valencia, Carla, Fatima, Hameeda, Nwankwo, Ijeoma · 2022 · Cureus
24. The Upcoming Weekly Tides (Semaglutide vs. Tirzepatide) against Obesity: STEP or SURPASS?
    Han Na Jung, Chang Hee Jung · 2022 · Journal of Obesity & Metabolic Syndrome
25. Cost-effectiveness analysis of five anti-obesity medications from a US payer's perspective
    Ainhoa Gómez-Lumbreras, Malinda Sunnita Tan, Lorenzo Villa Zapata, Sabrina Ilham, Jacob Craig Earl, Daniel C. Malone · 2023 · Nutrition Metabolism and Cardiovascular Diseases
26. Efficacy and safety of once‐weekly subcutaneous semaglutide on weight loss in patients with overweight or obesity without diabetes mellitus—A systematic review and meta‐analysis of randomized controlled trials
    Sharath Kommu, Richard L. Berg · 2024 · Obesity Reviews
27. Medications for obesity management: Effectiveness and value: A summary from the Institute for Clinical and Economic Review’s New England Comparative Effectiveness Public Advisory Council
    Atlas, Steven J, Kim, Kibum, Nhan, Emily, Touchette, Daniel R, Moradi, Ashton, Agboola, Foluso, Rind, David M, Beaudoin, Francesca L, Pearson, Steven D · 2023 · Journal of Managed Care & Specialty Pharmacy
28. Risk of major adverse cardiovascular events and all-cause mortality under treatment with GLP-1 RAs or the dual GIP/GLP-1 receptor agonist tirzepatide in overweight or obese adults without diabetes: a systematic review and meta-analysis
    Stefanou, Maria-Ioanna, Palaiodimou, Lina, Theodorou, Aikaterini, Safouris, Apostolos, Fischer, Urs, Kelly, Peter J., Dawson, Jesse, Katan, Mira, Katsanos, Aristeidis H., Lambadiari, Vaia et al. · 2024 · Therapeutic Advances in Neurological Disorders
29. Glucagon-Like Peptide-1 Based Therapies: A New Horizon in Obesity Management
    Son, Jang Won, Lim, Soo · 2024 · Endocrinology and Metabolism
30. Effectiveness and Safety of Semaglutide for Weight Loss in Patients With Inflammatory Bowel Disease and Obesity
    Aakash Desai, Himsikhar Khataniar, Jana G. Hashash, Francis A. Farraye, Miguel D. Regueiro, Gursimran Singh Kochhar · 2024 · Inflammatory Bowel Diseases
31. How do glucagon‐like Peptide‐1 receptor agonists affect measures of muscle mass in individuals with, and without, type 2 diabetes: A systematic review and meta‐analysis
    Oluwaseun Anyiam, Arash Ardavani, Rushdina Sofia Abdul Rashid, Avinash Panesar, ISKANDAR RAUF IDRIS · 2025 · Obesity Reviews
32. Development and complications of nutritional deficiencies after bariatric surgery
    Nele Steenackers, Bart Van der Schueren, Patrick Augustijns, Tim Vanuytsel, Christophe Matthys · 2022 · Nutrition Research Reviews
33. Giving weight to incretin-based pharmacotherapy for obesity-related sleep apnea: a revolution or a pipe dream?
    Ronald R. Grunstein, Thomas A. Wadden, Julia L. Chapman, Atul Malhotra, Craig L. Phillips · 2023 · SLEEP
34. Drugs for Treating Obesity
    Donna H. Ryan · 2021 · Handbook of experimental pharmacology
35. Efficacy of subcutaneous semaglutide compared to placebo for weight loss in obese, non-diabetic adults: a systematic review & meta-analysis
    Arastu, Naazneen, Cummins, Olivia, Uribe, Wanda, Nemec, Eric C. · 2022 · International Journal of Clinical Pharmacy
36. Glucagon-Like Peptide 1 Receptor Agonists: A Medication for Obesity Management
    Taha, Mohamad B., Yahya, Tamer, Satish, Priyanka, Laird, Rachel, Agatston, Arthur S., Cainzos-Achirica, Miguel, Patel, Kershaw V., Nasir, Khurram · 2022 · Current Atherosclerosis Reports
37. Novel Anti-obesity Therapies and their Different Effects and Safety Profiles: A Critical Overview
    Özge Telci Çaklılı, Mustafa Cesur, Dimitri P. Mikhailidis, Manfredi Rizzo · 2023 · Diabetes Metabolic Syndrome and Obesity
38. A model‐based approach to predict individual weight loss with semaglutide in people with overweight or obesity
    Anders Strathe, Deborah Bade Horn, Malte Selch Larsen, Domenica Rubino, Rasmus Sørrig, Marie Thi Dao Tran, Sean Wharton, Rune Viig Overgaard · 2023 · Diabetes Obesity and Metabolism
39. Safety and efficacy of glucagon-like peptide-1 receptor agonists on cardiovascular events in overweight or obese non-diabetic patients
    Sahib T Singh, Aakash Garg, Udaya S. Tantry, Kevin P. Bliden, Paul Alfred Gurbel, Martha Gulati · 2024 · Current Problems in Cardiology
40. Semaglutide utilization associated with reduced 90-day postoperative complications following single-level posterior lumbar fusion for patients with type II diabetes
    Anthony E Seddio, Michael J. Gouzoulis, Rajiv Siddhartha Vasudevan, Meera M. Dhodapkar, Sahir S. Jabbouri, Arya G. Varthi, Daniel R. Rubio, Jonathan Newman Grauer · 2024 · The Spine Journal
41. Efficacy of lifestyle modification combined with GLP-1 receptor agonists on body weight and cardiometabolic biomarkers in individuals with overweight or obesity: a systematic review and meta-analysis
    Jiaheng Chu, Haibo Zhang, Yin Feng Wu, Yue Huang, Tianren Zhu, Ziyi Zhou, Hui Wang · 2025 · EClinicalMedicine
42. The cardiovascular effects of novel weight loss therapies
    Muhammad Usman, Melanie Jane Davies, Michael E. Hall, Subodh Verma, Stefan D. Anker, Julio Rosenstock, Javed Butler · 2023 · European Heart Journal
43. Editorial: Obesity, metabolic phenotypes and COVID-19
    Despina Sanoudou, Michael A. Hill, Matthew J. Belanger, Kevin Arao, Christos Socrates Mantzoros · 2022 · Metabolism
44. Unlocking the multifaceted roles of GLP-1: Physiological functions and therapeutic potential
    AL-Noshokaty, Tohada M., Abdelhamid, Rehab, Abdelmaksoud, Nourhan M., Khaled, Aya, Hossam, Mariam, Ahmed, Razan, Saber, Toka, Khaled, Shahd, Elshaer, Shereen Saeid, Abulsoud, Ahmed I. · 2025 · Toxicology Reports
45. The pleiotropic effects of glucagon-like peptide-1 receptor agonists in patients with metabolic dysfunction-associated steatohepatitis: a review for gastroenterologists
    Naim Alkhouri, Michael Charlton, Meagan E. Gray, Mazen Noureddin · 2025 · Expert Opinion on Investigational Drugs
46. Misrepresentation of semaglutide in social media
    Lara Elisabeth Propfe, Roland Seifert · 2025 · Naunyn-Schmiedeberg s Archives of Pharmacology
47. Impact of nutritional‐behavioral and supervised exercise intervention following bariatric surgery: The BARI‐LIFESTYLE randomized controlled trial
    Friedrich C. Jassil, Alisia Carnemolla, Helen Kingett, Jacqueline Doyle, Amy Kirk, Neville Lewis, Gemma Montagut, Parastou Marvasti, David R Boniface, Adrian Carl Brown et al. · 2023 · Obesity
48. Glucagon‐like peptide 1 ( GLP ‐1) receptor agonists' use during pregnancy: Safety data from regulatory clinical trials
    Claire Parker, Craig Slattery, Donal J. Brennan, Carel Wynand le Roux · 2025 · Diabetes Obesity and Metabolism
49. Future perspectives in diabesity treatment: Semaglutide, a glucagon‑like peptide 1 receptor agonist (Review)
    Mariana Cornelia Tilinca, Robert Aurelian Tiucă, Cristina Niculas, Andreea Varga, Ioan Ţilea · 2021 · Experimental and Therapeutic Medicine
50. Medical and Surgical Treatment of Obesity
    Tirissa J. Reid, Judith Körner · 2022 · Medical Clinics of North America
51. Efficacy and tolerability of the subcutaneous semaglutide for type 2 diabetes patients: an updated systematic review and meta-analysis
    Hu, Shanshan, Su, Xiaorong, Fan, Guorong · 2023 · Diabetology & Metabolic Syndrome
52. Glucagon‐like peptide‐1 receptor agonists to expand the healthy lifespan: Current and future potentials
    Frederik Flindt Kreiner, Bernt Johan von Scholten, Peter Kurtzhals, Stephen Charles Langford Gough · 2023 · Aging Cell
53. Efficacy and safety of GLP-1RAs for people with obesity: A systematic review based on RCT and Bayesian network meta-analysis
    Hong Li, Guanzheng Yu, Qi Huang, Bao Yang, Juan Nie, Yinbei Liu, Xing Tu · 2024 · Biomedicine & Pharmacotherapy
54. Reframing prediabetes: A call for better risk stratification and intervention
    Sun H. Kim · 2024 · Journal of Internal Medicine
55. Why does GLP ‐1 agonist combined with GIP and/or GCG agonist have greater weight loss effect than GLP ‐1 agonist alone in obese adults without type 2 diabetes?
    Yuchen Jiang, Huijuan Zhu, Fengying Gong · 2024 · Diabetes Obesity and Metabolism
56. Current perspectives on the use of GLP-1 receptor agonists in obesity-related obstructive sleep apnea: a narrative review
    Ali El-Solh, Erin Gould, Keziah E Aibangbee, Tanya Jimerson, Rebecca Hartling · 2024 · Expert Opinion on Pharmacotherapy
57. Effects of semaglutide on vascular structure and proteomics in high-fat diet-induced obese mice
    Lin Yue, Shuchun Chen, Qingjuan Ren, Shu Niu, Xiaoyu Pan, Xing Chen, Zelin Li, Xiaoyi Chen · 2022 · Frontiers in Endocrinology
58. Nutritional priorities to support GLP-1 therapy for obesity: A joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and the Obesity Society
    Mozaffarian, Dariush, Agarwal, Monica, Aggarwal, Monica, Alexander, Lydia, Apovian, Caroline M., Bindlish, Shagun, Bonnet, Jonathan, Butsch, W. Scott, Christensen, Sandra, Gianos, Eugenia et al. · 2025 · Obesity Pillars
59. Management of type 2 diabetes, obesity, or nonalcoholic steatohepatitis with high‐dose GLP‐1 receptor agonists and GLP‐1 receptor‐based co‐agonists
    Goldenberg, Ronald M., Gilbert, Jeremy D., Manjoo, Priya, Pedersen, Sue D., Woo, Vincent C., Lovshin, Julie A. · 2024 · Obesity Reviews
60. Galectin-13 reduces membrane localization of SLC7A11 for ferroptosis propagation
    Hai‐Liang Zhang, Yi-Qing Guo, Shan Liu, Zhi-Peng Ye, Lichao Li, Bingxin Hu, Zhi‐Ling Li, Yuhong Chen, Gong‐Kan Feng, Hui-Qi Shen et al. · 2025 · Nature Chemical Biology
61. Vertical sleeve gastrectomy triggers fast β-cell recovery upon overt diabetes
    Lena Oppenländer, Subarna Palit, Kerstin Stemmer, Tobias Greisle, Michael Sterr, Ciro Salinno, Aimée Bastidas-Ponce, Annette Feuchtinger, Anika Böttcher, Md Ansarullah et al. · 2021 · Molecular Metabolism
62. Semaglutide Has Beneficial Effects on Non-Alcoholic Steatohepatitis in Ldlr-/-.Leiden Mice
    José A. Inia, Geurt Stokman, Martine C. Morrison, Nicole Worms, Lars Verschuren, Martien P. M. Caspers, Aswin L. Menke, Louis Petitjean, Li Chen, Mathieu Petitjean et al. · 2023 · International Journal of Molecular Sciences
63. Efficacy and Safety of Subcutaneous Semaglutide in Overweight or Obese Adults: A Subgroup Meta-Analysis of Randomized Controlled Trials
    Rui Zhang, Qinchuan Hou, Binghong Li, Ling Deng, Yumei Yang, Ting-xin Li, Xiaoqin Yao, Liang-liang Yang, Xi-long Lin, Yi-qian Liao et al. · 2022 · Frontiers in Endocrinology
64. Future directions in obesity pharmacotherapy
    Nick Finer · 2021 · European Journal of Internal Medicine
65. The pharmacodynamics-based prophylactic benefits of GLP-1 receptor agonists and SGLT2 inhibitors on neurodegenerative diseases: evidence from a network meta-analysis
    Ping‐Tao Tseng, Bing‐Yan Zeng, Chih-Wei Hsu, Chao‐Ming Hung, Andre Ferrer Carvalho, Brendon Stubbs, Yen‐Wen Chen, Tien‐Yu Chen, Wei‐Te Lei, Jiann-Jy Chen et al. · 2025 · BMC Medicine
66. Efficacy of GLP ‐1 Receptor Agonist‐Based Therapies on Cardiovascular Events and Cardiometabolic Parameters in Obese Individuals Without Diabetes: A Meta‐Analysis of Randomized Controlled Trials
    Yue Yin, Minghan Zhang, Qiuyu Cao, Lin Lin, Jieli Lu, Yufang Bi, Yuhong Chen · 2025 · Journal of Diabetes
67. Safety and Tolerability of Glucagon-Like Peptide-1 Receptor Agonists: A State-of-the-Art Narrative Review
    Setor Kwadzo Kunutsor, Samuel Seidu · 2025 · Drugs
68. Risk for Cancer With Glucagon-Like Peptide-1 Receptor Agonists and Dual Agonists
    Albert Ko, Yu-Cheng Chang, Furkan Bahar, Tsu Hsien Wang, Nutchapon Xanthavanij, Chun-Chiao Yu, Rebecca Jen-Ling Hsieh, Xin Ya See, Shao‐Wei Lo, Junmin Song et al. · 2025 · Annals of Internal Medicine
69. The Impact Once-Weekly Semaglutide 2.4 mg Will Have on Clinical Practice: A Focus on the STEP Trials
    Khaled A. Alabduljabbar, Werd Al‐Najim, Carel Wynand le Roux · 2022 · Nutrients
70. Are Current Guidelines Perpetuating Weight Stigma? A Weight-Skeptical Approach to the Care of Patients with Obesity
    Hagan, Scott, Nelson, Karin · 2023 · Journal of General Internal Medicine
71. Obstacles and Opportunities in Managing Coexisting Obesity and CKD: Report of a Scientific Workshop Cosponsored by the National Kidney Foundation and The Obesity Society
    Allon N. Friedman, Philip R. Schauer, Srinivasan Beddhu, Holly Kramer, Carel Wynand le Roux, Jonathan Q. Purnell, Duane Sunwold, Katherine R. Tuttle, Ania M. Jastreboff, Lee M. Kaplan · 2022 · American Journal of Kidney Diseases
72. Five-year Weight Loss Maintenance With Obesity Pharmacotherapy
    Michael A. Weintraub, Debra D’Angelo, Beverly G. Tchang, Ageline Sahagun, Clarissa Andre, Louis J. Aronne, Alpana P. Shukla · 2023 · The Journal of Clinical Endocrinology & Metabolism
73. Lifestyle Medicine for Obesity in the Era of Highly Effective Anti-Obesity Treatment
    Sannidhi, Deepa, Abeles, Ruth, Andrew, William, Bonnet, Jonathan P., Vitale, Kenneth, Niranjan, Varalakshmi, Gulati, Mahima, Pauly, Kaitlyn, Moran, Ryan, Alexander, Lydia et al. · 2025 · Nutrients
74. Cost-effectiveness of weight-management pharmacotherapies in Canada: a societal perspective
    Anamaria‐Vera Olivieri, Sergey Muratov, Sára Larsen, Maria Luckevich, Katalina Chan, Mark Lamotte, David C.W. Lau · 2024 · International Journal of Obesity
75. Lower Risk of Postoperative Complications and Rotator Cuff Retear Associated With Semaglutide Use in Patients with Type II Diabetes Mellitus Undergoing Arthroscopic Rotator Cuff Repair
    Anthony E Seddio, Jay T. Moran, Michael J. Gouzoulis · 2024 · Arthroscopy The Journal of Arthroscopic and Related Surgery
76. Treatment of Hypothalamic Obesity With GLP-1 Analogs
    Dimitri, Paul, Roth, Christian L · 2024 · Journal of the Endocrine Society
77. The Efficacy of Glucagon-like Peptide-1 (GLP-1) Receptor Agonists for Insufficient Weight Loss or Regain After Metabolic/Bariatric Surgery: A Systematic Review and Meta-analysis
    Joseph Kellett, Sara S. Soliman, Alicia Podwójniak, Michelle Minkanic, Gaurav Kumar, Brandon J. Goodwin, Hyo Joon Yang, Jana K. Elsawwah, Zoltán H. Németh · 2025 · Obesity Surgery
78. Efficacy and safety of danuglipron ( PF ‐06882961) in adults with obesity: A randomized, placebo‐controlled, dose‐ranging phase 2b study
    Clare Buckeridge, Sonia Cobain, Harold Edward Bays, Osamu Matsuoka, Yasushi Fukushima, Patricia Halstead, Nikolaos Tsamandouras, Nicole Sherry, Donal N. Gorman, Aditi R. Saxena · 2025 · Diabetes Obesity and Metabolism
79. Once-weekly 2.4 mg Semaglutide for Weight Management in Obesity: A Game Changer?
    Ides M. Colin, Anne-Catherine Gérard · 2022 · touchREVIEWS in Endocrinology
80. Effects of treatment for diabetes mellitus on testosterone concentrations: A systematic review
    Jolijn Van Cauwenberghe, Christophe E.M. De Block, Dirk Vanderschueren, Leen Antonio · 2022 · Andrology
81. An Updated Approach to Antiobesity Pharmacotherapy: Moving Beyond the 5% Weight Loss Goal
    Connor Enright, Elizabeth Thomas, David R. Saxon · 2023 · Journal of the Endocrine Society
82. Once-Weekly Subcutaneous Semaglutide 2.4 mg Injection is Cost-Effective for Weight Management in the United Kingdom
    Hera Sandhu, Weiwei Xu, Anamaria‐Vera Olivieri, Christopher Lübker, Inger Smith, Vasileios Antavalis · 2023 · Advances in Therapy
83. Seeking satiety: From signals to solutions
    Matthias H. Tschöp, Jeffrey M. Friedman · 2023 · Science Translational Medicine
84. Weight Loss Outcomes Among Early High Responders to Exenatide Treatment: A Randomized, Placebo Controlled Study in Overweight and Obese Women
    Rodgers, Megan, Migdal, Alexandra L., Rodríguez, Tahereh Ghorbani, Chen, Zsu-Zsu, Nath, Anjali K., Gerszten, Robert E., Kasid, Natasha, Toschi, Elena, Tripaldi, Juliet, Heineman, Brent et al. · 2021 · Frontiers in Endocrinology
85. Recent advances in peptide-based therapies for obesity and type 2 diabetes
    Bailey, Clifford J., Flatt, Peter R., Conlon, J. Michael · 2024 · Peptides
86. CVOT Summit Report 2023: new cardiovascular, kidney, and metabolic outcomes
    Oliver Schnell, Katharine D. Barnard-Kelly, Tadej Battelino, Antonio Ceriello, Helena Elding Larsson, Beatriz Fernández‐Fernández, Thomas M. Forst, Juan P. Frías, James R. Gavin, Francesco Giorgino et al. · 2024 · Cardiovascular Diabetology
87. Effects of glucagon-like peptide-1 receptor agonists on blood pressure in overweight or obese patients: a meta-analysis of randomized controlled trials
    Hon Jen Wong, Keith Zhi Xian Toh, Yao Hao Teo, Yao Neng Teo, Mark Y. Chan, Leonard L.L. Yeo, Pei Chia Eng, Benjamin Yong‐Qiang Tan, Xin Zhou, Qing Yang et al. · 2024 · Journal of Hypertension
88. Tolerability and Effectiveness of Glucagon-Like Peptide-1 Receptor Agonists in Patients with Inflammatory Bowel Disease
    Lindsay M. Clarke, Ravi Teja Pasam, Bryn E. Falahee, Pichamol Jirapinyo, Jessica Ravikoff Allegretti, Colleen R. Kelly · 2025 · Digestive Diseases and Sciences
89. The effect of GLP-1 receptor agonists on renal outcomes: a systematic review and meta-analysis
    Takaya Sasaki, Samantha My-Linh Giang, Jiajia Wu, Takashi Yokoo, Martin Gallagher, Rinaldo Bellomo, Ying Wang · 2025 · Nephrology Dialysis Transplantation
90. Effect of semaglutide 2.4 mg once weekly on 10‐year type 2 diabetes risk in adults with overweight or obesity
    Wilkinson, Lua, Holst‐Hansen, Thomas, Laursen, Peter N., Rinnov, Anders R., Batterham, Rachel L., Garvey, W. Timothy · 2023 · Obesity
91. Weight Loss and Body Composition after Compounded Semaglutide Treatment in a Real World Setting
    Chun, Elizabeth, Siojo, Alexandra, Rivera, David, Reyna, Kirsten, Legere, Henry, Joseph, Richard, Pojednic, Rachele · 2025 · Diabetes, Obesity and Metabolism
92. Differentiating monogenic and syndromic obesities from polygenic obesity: Assessment, diagnosis, and management
    Angela Fitch, Sonali Malhotra, Rushika Conroy · 2024 · Obesity Pillars
93. Semaglutide for weight loss: unanswered questions
    Ploutarchos Tzoulis, Stephanie E Baldeweg · 2024 · Frontiers in Endocrinology
94. Physical Activity and Excess Body Weight and Adiposity for Adults. American College of Sports Medicine Consensus Statement
    John M. Jakicic, Caroline Margaret Apovian, Daheia J. Barr‐Anderson, Anita P. Courcoulas, Joseph E. Donnelly, Panteleimon Ekkekakis A, Mark Hopkins, Mike Lambert, Melissa A. Napolitano, Stella Lucia Volpe · 2024 · Translational Journal of the American College of Sports Medicine
95. Nutritional and lifestyle supportive care recommendations for management of obesity with GLP-1 - based therapies: An expert consensus statement using a modified Delphi approach
    John L. Sievenpiper, Jamy D. Ard, Matthias Blüher, Wen Chen, John B. Dixon, A. Fitch, Linda Gigliotti, Kamlesh Khunti, Albert Lecube, MEJ Lean et al. · 2025 · Obesity Pillars
96. Is it Time to Expand Glucagon-like Peptide-1 Receptor Agonist Use for Weight Loss in Patients Without Diabetes?
    Wendy H. Updike, Olivia Pane, Rachel B. Franks, Faizah Saber, Farah Abdeen, Derek D. Balazy, Nicholas W. Carris · 2021 · Drugs
97. Racial Disparities and Cardiometabolic Risk: New Horizons of Intervention and Prevention
    Eftitan Y. Akam, Akua A. Nuako, Afkera Kesete Daniel, Fatima Cody Stanford · 2022 · Current Diabetes Reports
98. Diabetes Mellitus and Heart Failure With Preserved Ejection Fraction: Role of Obesity
    Aneesh Dhore-Patil, Tariq Thannoun, Rohan Samson, Thierry H. Le Jemtel · 2022 · Frontiers in Physiology
99. The effects of weight‐lowering pharmacotherapies on physical activity, function and fitness: A systematic review and meta‐analysis of randomized controlled trials
    Jobanputra, Rishi, Sargeant, Jack A., Almaqhawi, Abdullah, Ahmad, Ehtasham, Arsenyadis, Franciskos, Webb, David R., Herring, Louisa Y., Khunti, Kamlesh, Davies, Melanie J., Yates, Thomas · 2023 · Obesity Reviews
100. Female obesity: clinical and psychological assessment toward the best treatment
     Valeria Guglielmi, Riccardo Dalle Grave, Frida Leonetti, Anna Solini · 2024 · Frontiers in Endocrinology